The DOI matches its Crossref record.
Prognosis in Familial Amyotrophic Lateral Sclerosis: Progression and Survival in Patients with Glu100gly and Ala4val Mutations in Cu,Zn Superoxide Dismutase
Open accessAbstract
Familial amyotrophic lateral sclerosis (FALS) is an autosomal dominant neurodegenerative disorder affecting motor neurons and is associated with mutations in the Cu,Zn superoxide dismutase gene (SOD1) in a subset (approximately 15%) of FALS families. We analyzed 158 FALS patients from 27 families with mutations in SOD1. The mean age of onset was 45.5 +/- 8.9 years, and the mean duration of disease was 3.4 years. Forty-seven different mutations in SOD1 of FALS patients have been described worldwide. In North America, the ala4val mutation is the most common. In our patients, the ala4val mutation was associated with the most rapid progression of disease. The mean duration of disease was 1.0 +/- 0.4 years, which is significantly less than the mean duration of disease for FALS patients with mutations in SOD1 other than ala4val (p < 0.001). The duration of disease for the glu100gly mutation, 5.1 +/- 3.3 years, was significantly longer than the ala4val mutation (p < 0.001). We constructed Kaplan-Meier survival curves for the age of onset and duration of the disease for three groups of patients having mutations in SOD1: (1) ala4val; (2) glu100gly; and (3) ala4val, gly37arg, his43arg, gly85arg, gly93ala, glu100gly, leu106val, ile113thr, leu144phe, and val148gly, i.e., the entire patient population. There was no correlation between the genotype and the age of onset; 50% of affected individuals developed symptoms of ALS by the age of 47 years. As more data are collected, a more accurate prognostication of a patient's survival may be possible for specific SOD1 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prognostic factors in ALS: A critical review
Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., Traynor, B. G., & On Behalf of the Eurals Consortium (2009) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960802566824 · Cited by 1,172
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
Mejzini, R., Flynn, L. L., Pitout, I. L., Fletcher, S., Wilton, S. D., & Akkari, P. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01310 · Cited by 755
Kong, J., & Xu, Z. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-09-03241.1998 · Cited by 723
Clinical genetics of amyotrophic lateral sclerosis: what do we really know?
Andersen, P. M., & Al-Chalabi, A. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.150 · Cited by 687
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003715 · Cited by 565
The structural biochemistry of the superoxide dismutases
Perry, J. J. P., Shin, D. S., Getzoff, E. D., & Tainer, J. A. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.11.004 · Cited by 562
Controversies and priorities in amyotrophic lateral sclerosis
Turner, M. R., Hardiman, O., Benatar, M., Brooks, B. R., Chio, A., de Carvalho, M., Ince, P. G., Lin, C., Miller, R. G., Mitsumoto, H., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70036-x · Cited by 541
Risk factors for amyotrophic lateral sclerosis
Fang, F., Ingre, C., Roos, P., Kamel, F., & Piehl, F. (2015) · Clinical Epidemiology · doi:10.2147/clep.s37505 · Cited by 462
Olfaction in Parkinson's disease and related disorders
Doty, R. L. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.026 · Cited by 431
Moskovitz, J., Yim, M. B., & Chock, P. B. (2002) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2692 · Cited by 396
Wang, J., Slunt, H., Gonzales, V., Fromholt, D., Coonfield, M., Copeland, N. G., Jenkins, N. A., & Borchelt, D. R. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg312 · Cited by 306
Gene discovery in amyotrophic lateral sclerosis: implications for clinical management
Al-Chalabi, A., van den Berg, L. H., & Veldink, J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.182 · Cited by 287
Genetics of familial amyotrophic lateral sclerosis
Valdmanis, P. N., & Rouleau, G. A. (2008) · Neurology · doi:10.1212/01.wnl.0000296811.19811.db · Cited by 281
Centeno, E. G. Z., Cimarosti, H., & Bithell, A. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0258-4 · Cited by 268
Ince (1998) · doi:10.1046/j.1365-2990.1998.00108.x · Cited by 224
Genetic epidemiology of amyotrophic lateral sclerosis
Majoor‐Krakauer, D., Willems, P., & Hofman, A. (2003) · Clinical Genetics · doi:10.1046/j.0009-9163.2002.00001.x · Cited by 147
Nonnative SOD1 trimer is toxic to motor neurons in a model of amyotrophic lateral sclerosis
Proctor, E. A., Fee, L., Tao, Y., Redler, R. L., Fay, J. M., Zhang, Y., Lv, Z., Mercer, I. P., Deshmukh, M., Lyubchenko, Y. L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516725113 · Cited by 131
Chemosensory dysfunction in neurodegenerative diseases
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-63855-7.00020-4 · Cited by 78
Metadata
- Authors
- Juneja, T., Pericak-Vance, M. A., Laing, N. G., Dave, S., & Siddique, T.
- Venue
- Neurology
- Published
- 1997-01
- Volume
- 48
- Issue
- 1
- Pages
- 55-57
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2140595389
- Cited by
- 196
- References
- 0
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.